Primary Breast Lymphoma

Jennings, William C.; Baker, Ryan; Murray, Sunshine S.; Howard, C. Anthony; Parker, Donald E.; Peabody, Linda F.; Vice, Heather M.; Sheehan, W.; Broughan, Thomas A.

doi:10.1097/01.sla.0000254418.90192.59

Cited by 154 publications

(82 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than 80% of PBL are B-cell lymphomas (DLBCL), mostly CD20+. The most frequent histopathologic types are: diffuse large B-cell lymphoma (DLBCL) which accounts for up to 50% of all PBL, follicular lymphoma (FL)-15%, MALT lymphoma-12.2%, Burkitt's lymphoma (BL) and Burkittlike lymphoma-10.3% [10]. Other histological types of PBL include marginal zone lymphoma (MZL), small lymphocyticlymphoma (SLL), and anaplastic large cell lymphoma (ALCL).…”

Section: Discussionmentioning

confidence: 99%

“…Multivariate analyses also confirm that the early stage and use of RT are favourable prognostic factors. Jennings et al [10] in a Cox regression model, analyzing the tumour size and node status, revealed that the node status is the best single predictor of survival. The most common chemotherapy agents used in PBL have been those in the CHOP regimen.…”

Section: Discussionmentioning

confidence: 99%

“…In our case, mastectomy was performed. Jennings et al [10] reviewed all published PBL reports from 3 decades . Patient demographics, such as survival, recurrence and time to follow-up, were recorded, in addition to surgical, radiation and/or chemotherapeutic treat-ment(s).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosis Error: Carcinoma or Primary Breast Lymphoma? A Case Report and Literature Review

Fatemi¹,

Souaf²,

Jayi³

et al. 2013

ABCR

View full text Add to dashboard Cite

Introduction: Breast involvement by non-Hodgkin lymphoma is particularly rare in women. We describe the case of a patient with a rapidly growing, nodule in the right breast. On ultrasonography, the nodule was suspicious for breast carcinoma. Case presentation: A breast biopsy from a 73-year-old Moroccan women answered invasive ductal carcinoma grade 3 from Elston and Ellis. Patey was performed. Microscopic examination showed lymphoid proliferation confirmed on immunohistochemical analysis. Our patient was treated with chemotherapy. Conclusions: The rarity of breast lymphomas, and the problems related to the diagnosis and therapeutic choices with these tumors require molecular techniques in association with classical histological diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis Error: Carcinoma or Primary Breast Lymphoma? A Case Report and Literature Review

Fatemi¹,

Souaf²,

Jayi³

et al. 2013

ABCR

View full text Add to dashboard Cite

show abstract

“…The clinical and radiological presentation of both PBL and SBL may be similar to breast carcinoma but their treatments differ radically [5,7,14,15,16]. In fact, up until recently, surgery was considered the gold standard in the management of breast lymphomas [25,26], but recent studies have reported that mastectomy offered no benefit in the treatment of PBL and SBL and that therapy based on chemotherapy and/or radiotherapy provided better results in terms of survival and recurrence rates [17]. From this perspective, the cytological diagnosis of PBL and SBL can be extremely valuable for their management.…”

Section: Discussionmentioning

confidence: 99%

“…Conversely, intramammary reactive lymph node, sclerosing lobulitis, PBL and SBL do not necessarily require surgical excision, which would have a solely diagnostic value [5,7,14,15,16]. Therefore, an accurate, preoperative cytological diagnosis could allow proper and specific therapeutic procedures [17]. …”

Section: Introductionmentioning

confidence: 99%

Fine-Needle Cytology and Flow Cytometry Assessment of Reactive and Lymphoproliferative Processes of the Breast

Vigliar¹,

Cozzolino²,

Fernandez³

et al. 2012

Acta Cytologica

View full text Add to dashboard Cite

Objective: The breast may be affected by reactive and lymphoproliferative processes such as primary (PBL) or secondary (SBL) lymphoma, reactive intramammary lymph nodes and sclerosing lobulitis; imaging may be not specific and surgical treatment not indicated. We report an experience with fine-needle cytology (FNAC) combined with flow cytometry (FC) and immunocytochemistry (ICC) in the diagnosis of these processes. Study Design: Thirty-seven cases comprising intramammary lymph nodes (n = 15), sclerosing lobulitis (n = 2), PBL (n = 11) and SBL (n = 9) are reported. FNAC was used to prepare traditional smears, conventional ICC or FC. Cytological diagnoses were compared to the imaging data, checked by histology or follow-up and statistically evaluated. Results: Imaging was not conclusive in most PBL, SBL, sclerosing lobulitis and some intramammary lymph nodes. FNAC combined with FC and ICC provided a definitive diagnosis of intramammary lymph node, sclerosing lobulitis, PBL and SBL in 18 cases with indication of the specific subtype in 10 cases. Statistical analysis showed 90% sensitivity, 100% specificity, 100% positive predictive value and 89% negative predictive value. Conclusions: FNAC combined with FC and ICC is a helpful procedure for the diagnosis of reactive and lymphoproliferative processes of the breast. It may prevent unnecessary biopsy and speed up therapeutic procedures.

show abstract

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis

Wang

Jin

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Primary breast diffuse large B‐cell lymphoma (PB‐DLBCL) is an uncommon extranodal non‐Hodgkin's lymphoma (NHL), which was traditionally treated with anthracycline‐containing regimens followed by consolidative radiation therapy (RT) to add therapeutic benefits. The introduction of anti‐CD20 antibody rituximab for the treatment of B‐cell NHLs has significantly improved the clinical outcome of these malignant diseases. It is unclear, however, whether consolidative RT could still add therapeutic benefits for PB‐DLBCL patients treated with rituximab. To answer this important question, we used the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the impact of RT on the clinical outcomes of PB‐DLBCL patients in the rituximab era. Information on patient age, year of diagnosis, stage, race, laterality, and RT status for PB‐DLBCL patients diagnosed between 2001 and 2014 were extracted. Kaplan–Meier survival curves were plotted, and log‐rank test was used to compare the potential survival difference. Multivariate analysis using Cox proportional hazards model was employed to determine the impact of RT and other factors such as age, race, tumor laterality, stage, and year of diagnosis on survival. Among the 386 patients identified, the median follow‐up time was 45 months (range, 0–167 months); the median age was 64 years (range, 19–93 years); 33.9% of the patients were younger than 60 years of age; 69.9% of the patients were stage I; 79.0% were white; 51.8% received RT. The 5‐year OS and cause‐specific survival (CSS) for the whole cohort were 72.3% and 82.5%, respectively. The 5‐year OS was significantly superior for patients who received RT compared to those who did not receive RT (78.1% vs. 66.0%, P = 0.031). In multivariable analysis, RT remained significantly associated with improved OS (P = 0.026). In summary, our study suggests that RT still adds significant therapeutic benefits for patients with PB‐DLCBL in the rituximab era.

show abstract

Primary Breast Lymphoma

Abstract: Mastectomy offers no benefit in the treatment of PBL. Nodal status predicts outcome and guides optimal use of radiation and chemotherapy.

Cited by 154 publications

References 27 publications

Diagnosis Error: Carcinoma or Primary Breast Lymphoma? A Case Report and Literature Review

Diagnosis Error: Carcinoma or Primary Breast Lymphoma? A Case Report and Literature Review

Fine-Needle Cytology and Flow Cytometry Assessment of Reactive and Lymphoproliferative Processes of the Breast

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis

Contact Info

Product

Resources

About